Brentuximab vedotin
- Generic Name
- Brentuximab vedotin
- Brand Names
- Adcetris
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 914088-09-8
- Unique Ingredient Identifier
- 7XL5ISS668
- Background
Brentuximab vedotin, also known as Adcetrisยฎ, is an antibody-drug conjugate that combines an anti-CD30 antibody with the drug monomethyl auristatin E (MMAE). It is an anti-neoplastic agent used in the treatment of Hodgkin's lymphoma and systemic anaplastic large cell lymphoma. Brentuximab vedotin was initially approved in 2011. In January 2012, the drug labe...
- Indication
Brentuximab vedotin is indicated in adult patients for the treatment of previously untreated stage III or IV classical Hodgkin's lymphoma (cHL) in combination with doxorubicin, vinblastine, and dacarbazine. It is also indicated for the treatment of cHL post-autologous hematopoietic stem cell transplantation (auto-HSCT) in patients at high risk of relapse or ...
- Associated Conditions
- CD30-expressing Mycosis Fungoides (MF), Classical Hodgkin's Lymphoma, Peripheral T-Cell Lymphoma (PTCL), Primary Cutaneous Anaplastic Large Cell Lymphoma, Systemic Anaplastic Large Cell Lymphoma, Stage 3 Classical Hodgkin's Lymphoma
- Associated Therapies
- -
Fitness-adapted, Pembrolizumab-based Therapy for Untreated Classical Hodgkin Lymphoma Patients 60 Years of Age and Above
- Conditions
- Interventions
- First Posted Date
- 2022-06-03
- Last Posted Date
- 2024-07-03
- Lead Sponsor
- University of Virginia
- Target Recruit Count
- 44
- Registration Number
- NCT05404945
- Locations
- ๐บ๐ธ
University of Virginia, Charlottesville, Virginia, United States
๐บ๐ธRutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States
๐บ๐ธUniversity of Pennsylvania, Philadelphia, Pennsylvania, United States
Effectiveness of Concurrent Ultra-Low-Dose Total-Skin Electron Beam Therapy and Brentuximab Vedotin Given Quarterly Over 12 Months for Patients With Mycosis Fungoides
- First Posted Date
- 2022-05-03
- Last Posted Date
- 2024-07-05
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 30
- Registration Number
- NCT05357794
- Locations
- ๐บ๐ธ
MD Anderson Cancer Center, Houston, Texas, United States
Pembrolizumab and Brentuximab Vedotin in Subjects With Relapsed/Refractory T-cell Lymphoma
- First Posted Date
- 2022-04-06
- Last Posted Date
- 2024-06-05
- Lead Sponsor
- Yale University
- Target Recruit Count
- 43
- Registration Number
- NCT05313243
- Locations
- ๐บ๐ธ
Yale Smilow Cancer Hospital, New Haven, Connecticut, United States
Brentuximab Vedotin Plus DHAP in Relapsed or Refractory Hodgkin's Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2022-02-17
- Last Posted Date
- 2022-02-17
- Lead Sponsor
- National Cancer Center, Korea
- Target Recruit Count
- 30
- Registration Number
- NCT05243693
- Locations
- ๐ฐ๐ท
Hyeon-Seok Eom, Goyang, Gyeonggi-do, Korea, Republic of
A Safety Study of Brentuximab Vedotin in Participants With HIV
- Conditions
- Interventions
- First Posted Date
- 2022-02-17
- Last Posted Date
- 2023-02-14
- Lead Sponsor
- Seagen Inc.
- Registration Number
- NCT05244473
- Locations
- ๐บ๐ธ
University of California at San Francisco, San Francisco, California, United States
๐บ๐ธUniversity of Illinois at Chicago, Chicago, Illinois, United States
Pembrolizumab and Brentuximab Vedotin vs GDP and Stem Cell Transplant for Relapsed/Refractory Hodgkin Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2022-01-06
- Last Posted Date
- 2024-11-08
- Lead Sponsor
- Canadian Cancer Trials Group
- Target Recruit Count
- 84
- Registration Number
- NCT05180097
- Locations
- ๐ฆ๐บ
Austin Hospital, Heidelberg, Victoria, Australia
๐จ๐ฆVerspeeten Family Cancer Centre, London, Ontario, Canada
๐จ๐ฆTom Baker Cancer Centre, Calgary, Alberta, Canada
Open Label Extension Study of Brentuximab Vedotin in Early dcSSc
- Conditions
- Interventions
- First Posted Date
- 2021-12-08
- Last Posted Date
- 2024-11-18
- Lead Sponsor
- Lawson Health Research Institute
- Target Recruit Count
- 11
- Registration Number
- NCT05149768
- Locations
- ๐จ๐ฆ
Rheumatology Clinic, St. Joseph's Health Care, London, Ontario, Canada
Brentuximab Vedotin and Nivolumab for the Treatment of Relapsed/Refractory Classic Hodgkin Lymphoma Previously Treated With Brentuximab Vedotin or Checkpoint Inhibitors
- First Posted Date
- 2021-09-09
- Last Posted Date
- 2024-07-15
- Lead Sponsor
- Emory University
- Target Recruit Count
- 46
- Registration Number
- NCT05039073
- Locations
- ๐บ๐ธ
Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia, United States
๐บ๐ธEmory Saint Joseph's Hospital, Atlanta, Georgia, United States
Brentuximab Vedotin and Pembrolizumab in Treating Patients With Recurrent Peripheral T-Cell Lymphoma
- Conditions
- Recurrent Follicular T-Cell LymphomaRefractory Enteropathy-Associated T-Cell LymphomaRefractory Hepatosplenic T-Cell LymphomaRecurrent Angioimmunoblastic T-Cell LymphomaRefractory Follicular T-Cell LymphomaRefractory Nodal Peripheral T-Cell Lymphoma With TFH PhenotypeRefractory Subcutaneous Panniculitis-Like T-Cell LymphomaRecurrent Nodal Peripheral T-Cell Lymphoma With TFH PhenotypeRefractory Angioimmunoblastic T-Cell LymphomaRefractory Peripheral T-Cell Lymphoma, Not Otherwise Specified
- Interventions
- First Posted Date
- 2021-03-12
- Last Posted Date
- 2023-10-10
- Lead Sponsor
- Northwestern University
- Registration Number
- NCT04795869
- Locations
- ๐บ๐ธ
Northwestern University, Chicago, Illinois, United States
PACIFIC: Primary Mediastinal Large B-cell Lymphoma Treated with Antibody Therapy, Checkpoint Inhibitor in Frontline with ImmunoChemotherapy
- Conditions
- Interventions
- First Posted Date
- 2021-02-09
- Last Posted Date
- 2024-11-06
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 31
- Registration Number
- NCT04745949
- Locations
- ๐บ๐ธ
M D Anderson Cancer Center, Houston, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.